Makondi et al. found that targeting PRKACB may increase the responsiveness of colorectal tumors to irinotecan treatment 28, and Feng et al. also found pathological expressions of PRKACB in human colorectal cancer tissues infected with nucleobacteria 29. This evidence concerns the gene PRKACB and colorectal cancer.